ABL1 and acute lymphoblastic leukemia: However, with the growing use of immune-targeted therapies and the increased sensitivity of detection technologies, discrepancies in MRD assessment have emerged in some patients with Ph+ ALL, particularly where BCR::ABL1-based MRD levels remain consistently elevated compared to those detected by alternative methods.